GFAP and Alzheimer disease: Concentrations in people with AD and older controls from the MINDER/PCNoRAD studies are described in Supplementary Table 2 (median biomarker values were numerically higher than ex-players and controls in the case of NfL, p-tau217 and GFAP, and lower in the case of the Aβ 42:40 ratio).